Laboratory Tests Show Sambucol® Neutralises Common and Avian Flu Virus H5N1

Share Article

New research, carried out by Retroscreen Virology has indicated that Sambucol®, a patented formula, may fight the virulent Avian Flu virus. Results have been presented yesterday, Wednesday, in a press conference held in the Royal Society of Medicine, London. Speakers included Prof. Hannoun, Emeritus Professor at the Pasteur Institute and Dr. Mumcuoglu, developer of Sambucol®.

Laboratory trials held in a leading research institute, Retroscreen Virology Ltd, associated with the University of London found Sambucol® to be at least 99% effective against the Avian Flu virus H5N1. Sambucol® was effective at

significantly neutralising the infectivity of the virus in cell cultures. These results will also be presented during the International Conference on Bird Flu: “The First Pandemic of the 21st Century. A Central Role for Antivirals”, to be held at St. Bartholomew’s Hospital on January 19th-20th 2006.

Dr. Madeleine Mumcuoglu, is looking into further investigations into the activity of Sambucol® against Avian Flu on a wider scale.

In an earlier study (1995) Sambucol® was found to be effective against a wide range of influenza strains. Laboratory studies conducted at the Hebrew University – Hadassah Medical School, Jerusalem demonstrated the activity

of Sambucol® against human, swine, and avian influenza strains. Sambucol®'s efficacy was also demonstrated in two double blind, placebo controlled clinical studies. Sambucol® was shown to cut the duration and

severity of the common flu by up to half.

Notes to editors;

Sambucol® is based on an active substance isolated from the black elderberry.

Manufactured by Razei Bar Industries Israel, Sambucol® is available in 17 countries and in the UK is sold in Tesco, leading chemists, independent health food stores and wholesalers from £8.49.

For photography please visit the following site and enter the log in details:

FTP address:
user name: ftp_razeibar

password: 63+84675

For further press information please contact: Francesca Gaffey/Cheryl Davies, Communique Public Relations, Waterside, No2 Canal Street, Manchester, M1

3HE. Tel: 0161 242 5120/0161 242 5108 Fax: 0161 228 7391

For research information please visit: Retroscreen Virology Ltd. at:

For product information please visit:

Razei Bar Industries (1996) Ltd. At:

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Heidi Grevler

0794 916 2463
Email >
Visit website